ACS Award for Team Innovation

Sponsor: ACS Corporation Associates

Purpose: To highlight the value and importance of technical teams and teamwork to the chemical and allied industries by recognizing a multidisciplinary team for successfully moving an innovative idea to a product now in commercial use.

Nature: For each team member, the award consists of $3,000 and a certificate. Up to $1,000 for travel expenses to the meeting at which the award will be presented will be reimbursed to each team member. A certificate will also be provided to the employers of the team.

Eligibility: The team shall be multidisciplinary in nature and consist of not fewer than two (2) nor more than five (5) members. The team's work leading to this award must have been carried out primarily in the United States and the technical accomplishments of the team must be documented in the technical literature as a publication(s) or a patent(s). The output of the team must also demonstrate innovation, commercialization of a product or process, be of a special value to society, and of a nature that could only be achieved by professionals working together effectively. The rate of commercialization of the team's output will also be considered in the selection of the recipients of this award.

Deadline: November 1 (annual review).

Establishment & Support: The award was established in 1994, with financial support from the Committee on Corporation Associates of the American Chemical Society.

Nomination forms

Contact Information

Awards Office
American Chemical Society
1155 16th Street NW
Washington, DC 20036-4801
Phone: (202) 872-4408
Fax: (202) 776-8008
awards@acs.org

Recipient

2009
Hai-Ying Chen (Johnson Matthey Inc.), Neal W. Currier (Cummins Inc.), Howard S. Hess (Johnson Matthey Inc.), Bradlee J. Stroia (Cummins Inc.), Aleksey Yezerets (Cummins Inc.).

2008
Stanley Collins (3M) and Scott R. Culler (3M).

2007
Michael R. Barbachyn (Pfizer Inc.), Steven J. Brickner (Pfizer Inc.), Douglas K. Hutchinson (Abbott Laboratories) and Peter R. Manninen (Eli Lilly and Company)

2006
Charles A. Harbert (retired), B. Kenneth Koe (retired), Reinhard Sarges (retired), Albert Weissman (retired) and Willard M. Welch (retired), Pfizer Inc.

2005
S. Randall Holmes-Farley (Genzyme Drug Discovery and Development) and W. Harry Mandeville (Peptimmune, Inc. for work done at Genzyme Drug Discovery and Devleopment)

2004 Steven A. Van Slyke and Ching W. Tang (Eastman Kodak Company)

2003
Charles R. Harrison, George P. Lahm, Stephen F. McCann, and Keith D. Wing, (E.I. du Pont de Nemours & Co.,Inc.); and Rafael Shapiro (Bristol-Myers Squibb for work done at E.I. du Pont de Nemours & Co.,Inc.)

2002
Zhenan Bao, Ananth Dodabalapur, and John A. Rogers (Bell Laboratories, Lucent Technologies); Karl Amundson and Paul S. Drzaic (E Ink Corporation)

2001
Francis M. Houlihan and Omkaram Nalamasu (Bell Laboratories, Lucent Technologies), James M. Davidson and Ashok T. Reddy (Arch Chemicals, Inc.); and Arturo N. Medina (Arch Chemicals Semiconductor Photopolymers)

2000
Juan P. Arhancet, Hoe H. Chuah, Donald R. Kelsey, Joseph B. Powell, and Paul R. Weider (Shell Chemical Co.)

1999
Michael Showell and Manuel Venegas (Procter & Gamble Co.); and Richard R. Bott, David Estell, and Thomas P. Graycar (Genencor International)

1998
James H. Anderson, Ronald E. Chance, Richard DiMarchi, and Bruce H. Frank (Eli Lilly & Co.)

1997
David J. Carini, John V. Duncia, and Pancras C. Wong (DuPont Merck Pharmaceutical Co.); and Ronald S. Eydelloth and Michael L. Goldberg (Merck Research Laboratories)

1996
Satish Duggal, Thomas Hinman, Brian Stutts, David F. Thompson, and Raja Wusirika (Corning, Inc.)